Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
Rhea-AI Summary
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced a new $200 million share repurchase program effective from October 1, 2025, to December 31, 2026. The company plans to fund the buyback using its existing cash reserves.
As of June 30, 2025, Catalyst maintains a strong financial position with over $650 million in cash and cash equivalents and no funded debt. The repurchases may be executed through open market or privately negotiated purchases, with timing and volume depending on various market factors. The company maintains flexibility to suspend or terminate the program at any time.
Positive
- Strong cash position of over $650 million with no funded debt
- Significant share repurchase program of $200 million demonstrates confidence in business outlook
- Program execution maintains flexibility for business development and growth initiatives
- Solid operating results and significant cash flow generation
Negative
- Share repurchase program could limit cash available for potential acquisitions
- No guarantee of complete program execution as it can be suspended at any time
News Market Reaction
On the day this news was published, CPRX gained 6.14%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.6% during that session. Our momentum scanner triggered 45 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $156M to the company's valuation, bringing the market cap to $2.70B at that time.
Data tracked by StockTitan Argus on the day of publication.
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to
“Catalyst has a strong balance sheet, which reflected more than
Repurchases under the new share repurchase program may be made through a variety of methods, including open market or privately negotiated purchases. The timing and amount of shares repurchased will depend on the stock price, business and market conditions, corporate and regulatory requirements, alternative investment opportunities, acquisition opportunities and other factors. Catalyst is not obligated to repurchase any specific amount of shares of common stock, and the share repurchase program may be suspended or terminated at any time. Catalyst plans to use existing cash on hand to fund its share repurchase program.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) statements regarding Catalyst's plans, strategies, and the financial performance for its business, (ii) whether Catalyst will continue to be cash flow positive and profitable, (iii) whether Catalyst will be successful in executing on its strategic initiatives to expand its products and pipeline therapies to treat other rare diseases, (iv) statements regarding the amount, timing and execution of repurchases under the stock repurchase program, and (v) those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
What is the size of Catalyst Pharmaceuticals' (CPRX) new share repurchase program?
When will CPRX's share buyback program end?
How much cash does Catalyst Pharmaceuticals (CPRX) have available?
How will Catalyst Pharmaceuticals fund the CPRX stock buyback?
What methods will CPRX use for the share repurchase program?
